Company / R&D Expense
PTC Therapeutics, Inc. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$455.2M
FY2025
5-year range
$257.5M / $666.6M
FY2021-FY2025
Trend
-14.8%
vs FY2024
Sector context
#37 of 210
Health Care
What the data says
PTC Therapeutics, Inc.'s r&d expense of $455M is higher than 82% of companies in the Health Care sector (FY2025). R&D Expense has fluctuated over the past 10 years, ranging from $117M in FY2017 to $667M in FY2023.
Based on SEC 10-K filings.
$455M in FY2025 with a 5-year CAGR of +21.5%. Top quartile in the Health Care sector.
Declined from $667M to $455M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -1.6%
- 5-Year CAGR
- +21.5%
- 10-Year CAGR
- -
Sector benchmark
Top 18% in Health CareTop 18% of 210This company $455.2M Sector average $644.0M
▼
-29.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +21.5%, indicating consistent growth.
- In FY2025, r&d expense decreased 14.8% year-over-year.
- Ranks #37 out of 210 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 0.95 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $455.2M | -14.8% |
| FY2024 | $534.5M | -19.8% |
| FY2023 | $666.6M | +39.6% |
| FY2022 | $477.6M | +85.5% |
| FY2021 | $257.5M | +49.7% |
| FY2020 | $172.0M | -33.2% |
| FY2019 | $257.5M | +49.7% |
| FY2018 | $172.0M | +46.4% |
| FY2017 | $117.5M | -0.2% |
| FY2016 | $117.6M | -3.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026